Acquiring Expertise for Improved Patient Outcomes in Immune Thrombocytopenia

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians pertaining to the topic of improved patient outcomes in immune thrombocytopenia (ITP). 

Immune thrombocytopenia is a heterogenous disorder in which patients develop an autoimmune response to platelets that results in severe cytopenia and places them at risk for bleeding events. The lack of specific criteria makes diagnosis challenging for clinicians, and understanding the pathogenesis is crucial to treatment management. Standard first-line therapy does not result in sustained responses in the majority of patients. In addition, the personalization of therapy and supportive care to patients’ individual goals of treatment remains an unmet need. Due to this, it is imperative that clinicians receive educational opportunities to stay up to date on new insights and options for improving patient outcomes in ITP.

To address the knowledge gaps experienced by clinicians regarding improved patient outcomes in ITP, i3 Health provided a continuing medical education (CME)–/nursing continuing professional development (NCPD)–approved strategy session. The activity was made available on i3 Health’s website starting on February 28, 2022, until February 27, 2023. Two experts in the field of immune thrombocytopenia led the activity: Howard A. Liebman, MD, a Professor of Medicine and Pathology at the University of Southern California Keck School of Medicine; and Allison Miller Imahiyerobo, MSN, APN, an Advanced Practice Nurse of Hematology and Oncology at the Physicians of Englewood.

A total of 924 individuals participated in the activity with 638 completing the activity for credit. Most learners were registered nurses, followed by physicians, nurse practitioners, physician assistants, and those who chose “other” as their profession.

The baseline data collected revealed knowledge gaps in the following areas: assessing the pathogenesis of ITP and its relationship to diagnosis and therapeutic approach; evaluating the efficacy, safety, and mechanisms of action of current and emerging ITP therapies; and applying supportive care strategies that can be used to help patients with ITP achieve their goals of therapy.

Participants were given a matching pretest and posttest at the beginning and end of the activity, respectively. The posttest assessment revealed a 73% increase in understanding the diagnosis of ITP (pretest 24% versus posttest 97%); a 58% increase in understanding the efficacy of rilzabrutinib therapy for chronic ITP (pretest 42% versus posttest 100%); a 45% increase in understanding adverse event monitoring for treatment with eltrombopag (pretest 55% versus posttest 100%); and a 74% increase in understanding management strategies to reduce bleeding risk (pretest 23% versus posttest 97%).

Upon completion of the activity, 91% of learners reported that they felt more confident in treating their patients with ITP, and 90% reported that they felt that the material presented would be used to improve the outcomes of their patients.

The data revealed by the posttest assessment affirm the effectiveness of online educational content pertaining to the topic of new insights for improved patient outcomes in ITP. Based on these data, i3 Health has determined that the multidisciplinary team may benefit from CME/NCPD activities that provide ITP education on the pathogenesis of ITP and its relationship to diagnosis and therapeutic approach; efficacy and safety of current and emerging ITP therapies; and supportive care strategies to help patients with ITP achieve their goals of therapy.

Resources

i3 Health (2023). New insights and avenues for improved patient outcomes in immune thrombocytopenia: outcomes activity report. Data on file. 

Related Articles

Responses

Your email address will not be published. Required fields are marked *